BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Healthcare Technologies, Ltd. (HCTL) Announces Termination Of Agreement With ImmvaRx, Inc.


1/30/2006 11:43:17 AM

PETACH TIKVA, Israel, January 30 /PRNewswire-FirstCall/ -- Healthcare Technologies, Ltd. announced today that the previously disclosed agreement between Healthcare, ImmvaRx, Inc. and Gamida for Life BV, dated as of July 26, 2005, has been terminated in accordance with its terms.

About Healthcare Technologies

Healthcare Technologies through it subsidiaries and affiliate, Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

About ImmvaRx

ImmvaRx is an immunotherapeutics biotechnology company focusing on immune system based therapies. Specifically, the company develops therapeutic, diagnostic, and research products with an initial focus on the Adenocarcinoma family of cancers and Type 1 allergies. The immunotherapies include both humanized antibody and vaccine treatments.

SAFE HARBOR: This press release contains certain forward looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Many factors could cause the actual results, performance or achievements of Healthcare or the above described transaction to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking.

FOR: Healthcare Technologies Ltd. CONTACT: Eran Rotem, CFO, +972-3-9277232/3

Healthcare Technologies Ltd.

CONTACT: Contact: Healthcare Technologies Ltd., Eran Rotem, CFO,+972-3-9277232/3



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES